Pleiotropic effects of fibrates

Current Atherosclerosis Reports

Volumn 7, Issue 5, 2005, Pages 396-401

  Chinetti Gbaguidi, Giulia ^b   Fruchart, Jean Charles ^b   Staels, Bart ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; APOLIPOPROTEIN A1; BEZAFIBRATE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CIPROFIBRATE; CLOFIBRATE; COUMARIN DERIVATIVE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE INHIBITOR; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME ACTIVITY; FOAM CELL; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION REGULATION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIGAND BINDING; LIPID METABOLISM; LIPID TRANSPORT; LIVER TOXICITY; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PRIMARY PREVENTION; PROTEIN METABOLISM; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 28044440697     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-005-0053-x     Document Type: Review

References (58)

1. Barbier O, Torra IP, Duguay Y, et al.: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22:717-726.
2. Marx N, Sukhova G, Collins T, et al.: PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
3. Delerive P, Martin-Nizard F, Chinetti G, et al.: PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway. Circ Res 1999, 85:394-402.
4. Staels B, Koenig W, Habib A, et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators. Nature (London) 1998, 393:790-793.
5. Chinetti G, Griglio S, Antonucci M, et al.: Activation of peroxisome proliferator-activated receptors a and g induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273:25573-25580.
6. Chinetti G, Gbaguidi GF, Griglio S, et al.: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411-2417.
7. Dharancy S, Malapel M, Perlemuter G, et al.: Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005, 128:334-342.
8. Blanquart C, Mansouri R, Fruchart JC, et al.: Different ways to regulate the PPARalpha stability. Biochem Biophys Res Commun 2004, 319:663-670.
9. Blanquart C, Barbier O, Fruchart JC, et al.: Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem 2002, 277:37254-37259.
10. Blanquart C, Mansouri R, Paumelle R, et al.: The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol 2004, 18:1906-1918.
11. Kliewer SA, Sundseth SS, Jones SA, et al.: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and g. Proc Natl Acad Sci U S A 1997, 94:4318-4323.
12. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors a and d. Proc Natl Acad Sci U S A 1997, 94:4312-4317.
13. Devchand PR, Keller H, Peters JM, et al.: The PPARa-leukotriene B4 pathway to inflammation control. Nature (London) 1996, 384:39-43.
14. Delerive P, Furman C, Teissier E, et al.: Oxidized phospholipids activate PPARa in a phospholipase A2-dependant manner. FEBS Lett 2000, 471:34-38.
15. Duez H, Lefebvre B, Poulain P, et al.: Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005, 25:585-591.
16. Vu-Dac N, Gervois P, Jakel H, et al.: Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003, 278:17982-17985.
17. Patsouris D, Mandard S, Voshol PJ, et al.: PPARalpha governs glycerol metabolism. J Clin Invest 2004, 114:94-103.
18. Chinetti G, Lestavel S, Bocher V, et al.: PPARa and PPARg activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med 2001, 7:53-58.
19. Haraguchi G, Kobayashi Y, Brown ML, et al.: PPARalpha and PPARgamma activators suppress the monocyte-macrophage apolipoprotein B48 receptor. J Lipid Res 2003, 44:1224-1231.
20. Gbaguidi GF, Chinetti G, Milosavljevic D, et al.: Peroxisome proliferator-activated receptor (PPAR) agonists decrese lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Lett 2002, 512:85-90.
21. Li L, Beauchamp MC, Renier G: Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 2002, 165:101-110.
22. Chinetti G, Lestavel S, Fruchart JC, et al.: Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res 2003, 92:212-217.
23. Ghosh S, Natarajan R: Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. Biochem Biophys Res Commun 2001, 284:1065-1070.
24. Chinetti G, Zawadski C, Fruchart JC, Staels B: Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 2004, 314:151-158.
25. Delerive P, Gervois P, Fruchart JC, Staels B: Induction of IkBa expression as a mechanism contributing to the anti-inflammatory activities of PPARa activators. J Biol Chem 2000, 275:36703-36707.
26. Delerive P, De Bosscher K, Vanden Berghe W, et al.: DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol 2002, 16:1029-1039.
27. Kleemann R, Gervois PP, Verschuren L, et al.: Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF{kappa}B ∼C/EBP- {beta} complex formation. Blood 2002, 101:545-551.
28. Gervois P, Vu-Dac N, Kleemann R, et al.: Negative regulation of human fibrinogen gene expression by PPAR{alpha} agonists via inhibition of C/EBPbeta. J Biol Chem 2001, 276:33471-33477.
29. Gervois P, Kleemann R, Pilon A, et al.: Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem 2004, 279:16154-16160.
30. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S41-S45.
31. Lin R, Liu J, Gan W, Yang G: C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 2004, 27:1537-1543.
32. Neve BP, Corseaux D, Chinetti G, et al.: PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001, 103:207-212.
33. Marx N, Mackman N, Schonbeck U, et al.: PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001, 103:213-219.
34. Shu H, Wong B, Zhou G, et al.: Activation of PPARa or g reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000, 267:345-349.
35. Hourton D, Delerive P, Stankova J, et al.: Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages. Biochem J 2001, 354:225-232.
36. Barbier O, Villeneuve L, Bocher V, et al.: The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem 2003, 278:13975-13983.
37. Forman HJ, Torres M: Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002, 166:S4-S8.
38. Teissier E, Nohara A, Chinetti G, et al.: Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPARalpha activation properties. Circ Res 2004, 95:1174-1182.
39. Inoue I, Goto S, Matsunaga T, et al.: The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001, 50:3-11.
40. Marx N, Kehrle B, Kohlhammer K, et al.: PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002, 90:703-710.
41. Ericsson C, Hamsten A, Nilsson J, et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853.
42. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
43. Frick MH, Syvanne M, Nieminen MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997, 96:2137-2143.
44. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
45. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
46. Sebestjen M, Keber I, Zegura B, et al.: Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 2004, 92:1129-1135.
47. Despres JP, Lemieux I, Pascot A, et al.: Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2003, 23:702-703.
48. Madej A, Okopien B, Kowalski J, et al.: Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998, 36:345-349.
49. Kowalski J, Okopien B, Madej A, et al.: Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther 2003, 41:241-247.
50. Okopien B, Krysiak R, Kowalski J, et al.: The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004, 176:327-335.
51. Jonkers IJ, Mohrschladt MF, Westendorp RG, et al.: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002, 112:275-280.
52. Ansquer JC, Foucher C, Rattier S, et al.: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005, 45:485-493.
53. Tambaki AP, Rizos E, Tsimihodimos V, et al.: Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J Cardiovasc Pharmacol Ther 2004, 9:91-95.
54. Tsimihodimos V, Kostoula A, Kakafika A, et al.: Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004, 9:27-33.
55. Dierkes J, Westphal S, Luley C: The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Safety 2004, 3:101-111.
56. Luc G, Jacob N, Bouly M, et al.: Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. J Cardiovasc Pharmacol 2004, 43:452-453.
57. Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005, 95:120-122.
58. Blum A, Seligmann H, Livneh A, Ezra D: Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction. Isr J Med Sci 1992, 28:47-49.